Foghorn Therapeutics Inc
FHTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$259.52M
Close$
Share Statistics
| Market cap | $259.52 Million |
|---|---|
| Enterprise Value | $271.13 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.18 |
| Beta | 2.86 |
| Outstanding Shares | 70,629,419 |
Return
| Return on Equity | 79.69% |
|---|---|
| Return on Assets | -31.75% |
| Return on Invested Capital | -43.75% |
Valuation & Multiples
| P/E Ratio | -4.46 |
|---|---|
| PEG | 7.45 |
| Price to Sales | - |
| Price to Book Ratio | -2.06 |
| Enterprise Value to Revenue | 7.38 |
| Enterprise Value to EBIT | -4.06 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.29 |
| Debt to Equity | -0.98 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.24
Average shareholder expectationRevenue Estimate
$6.81 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.22
Average shareholder expectationRevenue Estimate
$7.09 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 63.76%▼ 0.14% |
|---|---|
| Total Invested | $219.77M▲ 3.45% |
| Investors Holding | 105▲ 1.00% |
ESG Score
No data
About Foghorn Therapeutics Inc
95 employeesFoghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. The ...